Medical Mycology Unit, Department of Microbiology, Vallabhbhai Patel Chest Institute, University of Delhi, Delhi, India; email:
National Reference Laboratory for Antimicrobial Resistance in Fungal Pathogens, Vallabhbhai Patel Chest Institute, University of Delhi, Delhi, India.
Annu Rev Microbiol. 2023 Sep 15;77:583-602. doi: 10.1146/annurev-micro-032521-015858. Epub 2023 Jul 5.
is a multidrug-resistant fungal pathogen that presents a serious threat to global human health. Since the first reported case in 2009 in Japan, infections have been reported in more than 40 countries, with mortality rates between 30% and 60%. In addition, has the potential to cause outbreaks in health care settings, especially in nursing homes for elderly patients, owing to its efficient transmission via skin-to-skin contact. Most importantly, is the first fungal pathogen to show pronounced and sometimes untreatable clinical drug resistance to all known antifungal classes, including azoles, amphotericin B, and echinocandins. In this review, we explore the causes of the rapid spread of . We also highlight its genome organization and drug resistance mechanisms and propose future research directions that should be undertaken to curb the spread of this multidrug-resistant pathogen.
是一种具有多重耐药性的真菌病原体,对全球人类健康构成严重威胁。自 2009 年在日本首次报告病例以来,已有 40 多个国家报告了 感染病例,死亡率在 30%至 60%之间。此外,由于其通过皮肤接触传播的效率很高, 有在医疗机构(尤其是老年患者护理院)中引发暴发的潜力。最重要的是, 是第一个对所有已知抗真菌类药物(包括唑类、两性霉素 B 和棘白菌素类)均表现出明显且有时无法治疗的临床药物耐药性的真菌病原体。在这篇综述中,我们探讨了 迅速传播的原因。我们还强调了其基因组组织和耐药机制,并提出了应开展的未来研究方向,以遏制这种具有多重耐药性的病原体的传播。